Aveo no hit on its opening day Boston Globe The disappointing market debut of Aveo, which develops cancer treatments, is the latest sign that hopes for a biotechnology IPO revival might be premature. ... Aveo Pharmaceutical shares drop in trading debut The Associated Press AVEO Pharmaceuticals IPO Raises 23% Less Than Sought BusinessWeek Biotech IPO: AVEO Pharma Develops Cancer Therapeutics Seeking Alpha (blog) MarketWatch (press release)  - Reuters  - Boston Herald all 221 news articles »